- Language: English
- 204 Pages
- Published: June 2013
- Region: Global
Next Generation Sequencing Report 2013
- ID: 2668553
- September 2013
- Region: Global
- 136 Pages
- Yole Développement
NGS technologies drive the way toward personalized medicine
NGS technologies have demonstrated the capacity to sequence DNA at unprecedented speed, enabling previously unimaginable novel healthcare applications. By providing valuable data on patient genomes, NGS technologies are filling the gap separating traditional and personalized medicine. Along with a global shift toward personalized medicine and through the development of advanced bioinformatic tools, NGS technologies will have a striking impact on cancer management, treatments of rare diseases and future developments of genetic therapies.
The change will be gradual, starting with oncology where personalized medicine is more likely to be accepted. Physicians will have to change their way of working to take full advantage of this giant leap forward in medicine. To do so, medical school coursework will likely evolve in the near future to integrate how to work with genomics data.
The Next Generation Sequencing market is poised to reach $4.4B in 2018!
Starting its transition from research to clinical market, the Next Generation Sequencing (NGS) market will sharply grow from $2.2B to $4.4B in 2018.
That impressive growth will be fueled by huge investments recently made by Diagnostic companies (Thermo Fisher Scientific, Qiagen, Illumina…) associated with the market entry of new products (PII and PIII, Qiagen's benchtop, Oxford Nanopore…). Previously, the high cost of both sequencing machines and consumables limited the wide adoption of this technology. Today, those drawbacks have been resolved with the development of Next Generation Sequencing Technologies. The attractiveness of the NGS business has caused the number of suppliers to sharply increase over the last five years. Among them, Illumina is positioned in first place with around 46% of market share. Thermo Fisher Scientific, in second place, is the most important challenger.
This analysis provides 2013-2018 market data, along with player market shares at both equipment and consumable levels. Moreover, positioning strategy of each supplier has been analyzed in the document. Discover the NGS market's complex organization, split in four segments.
The market segmentation is a tool used to provide a vision of the market. Based on technical and economic criteria, fours segments have been identified: research, forensics, diagnostics and consumer.
Until recently, uses of Next Generation Sequencing tools were limited to research (human whole genome, exome, small genome, targeted, transcriptome, RNA profiling, chIP-Seq, metagenomics…). Nowadays, NGS technologies have found applications mainly in two fields: clinical diagnostics and forensics. This investigation describes both current and future applications.
Next Generation Sequencing technologies overview
In April 2003, human genome project was declared complete. This first human genome sequencing took 13 years, mobilized 20000 researchers and cost $3B!
Since the early 2000s, sequencing technologies have come a long way from Sanger sequencing (also called 1st generation sequencing) used for the human genome project to the Next Generation Sequencing technologies available today.
By sequencing a large number of DNA molecules in parallel after PCR amplification, technology developers have been able to sharply increase machine throughput by a factor of 10, along with a steep price reduction.
The launch of a new detection method based on electrochemical detections was also a huge step forward for the sequencing world. Today, based on these new technologies, we can sequence the whole human genome in less than three hours with one laboratory technician and a total cost around $1000.
Technologies under development are poised to extend the boundaries with a targeted sequencing cost of $100.
All technologies currently in use and those under development are presented in our report. Benchmarking is also presented for eight different sequencing applications.
New opportunities arise for cartridge makers
The wide adoption of NGS technology has changed the way NGS suppliers are generating revenue. A shift occurred in the sales mix, moving from instruments to consumables which have a higher gross margin than instruments. This leads to an increase in revenue based on consumable sales. The number of NGS Platforms used worldwide will exploded in the next several years and the run time will continue to decrease. Therefore, the market of NGS consumables will follow.
The NGS Consumables Market is forecast to grow to $3.1B in 2018, the result of several millions of cartridges being sold each year. For now, glass and silicon are the preferred materials used.
Key report features:
- 2013-2018 Next Generation Sequencing equipment market
- 2013-2018 Next Generation Sequencing consumable market
- Market segmentation which highlights current and future applications
- Overview of sequencing technologies and cartridges associated
- Detailed supply chain and business model analysis highlighting the major changes expected over next few years
- Company profiles of the main players
- Provide an overview of global NGS market both at equipment and consumable levels.
- Present main players and technologies involved
- Analyze both technical and market trends
- Focus on microfluidic consumable cartridges used for genome testing
- Supply Chain analysis
**Please contact our customer services for other license types** SHOW LESS READ MORE >
1. Executive summary
3. Market data
- Global Next Generation Sequencing market in $M 2013-2018
- Next Generation Sequencing equipment market, in units, $M 2013-2018
- Next Generation Sequencing consumable market, in units, $M 2013-2018
4. Market segmentation
5. Next Generation Sequencing technologies overview
- From biotechnology point of view
- From cartridge point of view
6. Value chain and supply chain
7. Market trends and challenges
8. Company profiles
· Summary and conclusions (p.136)
- Azco Biotech Inc
- Base 4
- Genia Technologies
- Noblegen Biosciences
- Oxford Nanopore Technologies
- Pacific Biosciences
- Roche 454
- Stratos Genomics Inc.
- Thermo Fisher Scientific